In 2020, UPLIZNA (inebilizumab-cdon) and ENSPRYNG (satralizumab-mwge) were approved for the treatment of NMOSD in adult patients with the same AQP4 antibody. However, there is a need for improvement in NMOSD treatments. Therefore, testing a new treatment or looking at different combinations of existing treatments is necessary. The emerging products in the NMOSD pipeline are limited.
DelveInsight’s “Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neuromyelitis Optica Spectrum Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Neuromyelitis Optica Spectrum Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Neuromyelitis Optica Spectrum Disorder: An Overview
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). NMOSD is regarded as an autoimmune disease, though the exact cause of the autoimmunity is unknown.
It is now recognized that most patients satisfying the current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. NMOSD may be confused with multiple sclerosis (MS) in its early stages. There are two types of Neuromyelitis optica (NMO), monophasic NMO, in which a single acute attack of NMO lasts for about 1 month and does not recur within 3 years and occurs very rarely, and the other one is relapsing NMO, which is a chronic form of NMO that involves flare-ups and periods of remission.
Neuromyelitis Optica Spectrum Disorder Market Key Facts
-
According to the National Organization for Rare Disorders (NORD) (2021), the prevalence of NMOSD is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry. Individuals of any age may be affected, but typically NMOSD, especially cases seropositive for AQP4-IgG, occurs in late middle-aged women.
-
A study by Lechner et al. (2020) estimated the prevalence of pediatric NMOSD between March 2017 and February 2019 in Germany. The estimated prevalence rate of NMOSD was 0.147 per 100,000 persons with 20 pediatric NMOSD patients; considering only the 12 AQP4-ab positive patients, it was 0.088 per 100,000.
-
As per the Genetic and Rare Diseases Information Center (GARD) 2022, in the US, NMOSD is estimated to be fewer than 5,000.
Neuromyelitis Optica Spectrum Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Neuromyelitis Optica Spectrum Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Neuromyelitis Optica Spectrum Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Neuromyelitis Optica Spectrum Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Reports Cover the Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology Segmented by –
-
Total Prevalent Cases of Neuromyelitis Optica Spectrum Disorder in the 7MM (2019–2032)
-
Total Diagnosed Prevalent Cases of Neuromyelitis Optica Spectrum Disorder in the 7MM (2019–2032)
-
Treated Cases of Neuromyelitis Optica Spectrum Disorder in the 7MM (2019–2032)
-
Gender-specific Cases of Neuromyelitis Optica Spectrum Disorder in the 7MM (2019–2032)
Neuromyelitis Optica Spectrum Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuromyelitis Optica Spectrum Disorder market or expected to be launched during the study period. The analysis covers the Neuromyelitis Optica Spectrum Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neuromyelitis Optica Spectrum Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Neuromyelitis Optica Spectrum Disorder Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Neuromyelitis Optica Spectrum Disorder Therapeutics Analysis
Several major pharma and biotech giants are actively developing Neuromyelitis Optica Spectrum Disorder (NMOSD) therapies. RemeGen is leading the therapeutics market with its Neuromyelitis Optica Spectrum Disorder (NMOSD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Include:
-
RemeGen
-
Alexion Pharmaceuticals
-
Reistone Biopharma
-
Nihon Pharmaceutical
-
Harbour BioMed
-
Bio-Thera Solutions
-
Abide Therapeutics
-
Bionure
-
TG Therapeutics
-
ENDECE
-
Boston Pharmaceuticals
-
NovelMed
And Many Others
Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Covered in the Report Include:
-
AIM Biologicals: Aeterna Zentaris
-
ARN-6039: Boston Pharmaceuticals
-
B001: Shanghai Pharmaceuticals Holding Co., Ltd.
-
BAT4406F: Bio-Thera Solutions
-
HBM9161: Harbour BioMed
-
LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
-
NDC-1308: ENDECE
-
Ravulizumab: Alexion Pharmaceuticals
-
SHR1459: Reistone Biopharma
-
Telitacicept: RemeGen
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Neuromyelitis Optica Spectrum Disorder Competitive Intelligence Analysis
4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance
5. Neuromyelitis Optica Spectrum Disorder Disease Background and Overview
6. Neuromyelitis Optica Spectrum Disorder Patient Journey
7. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Neuromyelitis Optica Spectrum Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuromyelitis Optica Spectrum Disorder Unmet Needs
10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment
11. Neuromyelitis Optica Spectrum Disorder Marketed Products
12. Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Latest Therapeutic Advances
13. Neuromyelitis Optica Spectrum Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Neuromyelitis Optica Spectrum Disorder Market Outlook (In US, EU5, and Japan)
16. Neuromyelitis Optica Spectrum Disorder Access and Reimbursement Overview
17. KOL Views on the Neuromyelitis Optica Spectrum Disorder Market
18. Neuromyelitis Optica Spectrum Disorder Market Drivers
19. Neuromyelitis Optica Spectrum Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
Other Trending Healthcare Reports By DelveInsight
Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline Insight
“Neuromyelitis Optica Spectrum Disorder (NMOSD) – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ drugs in Neuromyelitis Optica Spectrum Disorder (NMOSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/